Creative Biolabs provides customer with cutting-edge CellRapeutics™ Chimeric Antigen Receptor (CAR) against a series of Germ cell tumor specific antigens, which is based on a great amount of researches and many years of experience. As a reputable service provider, we are dedicated to highly tailored service in order to meet your unique requirements.
Germ cell tumor (GCT) is a rare kind of cancer which derives from germ cells, which can be benign or malignant (cancer). The most common categories are testicular germ cell tumors (seminoma and non-seminoma) and ovarian germ cell tumors, however they can also spread to other parts of the body which leads to various symptoms. The etiology of germ cell tumor is still unclear. The treatment for germ cell tumor usually includes surgery, chemotherapy, radiation, bone marrow transplantation or a combination of these approaches. However, these traditional treatments are not highly effective and can cause the risk of potential complications. In decades, GCT therapy is focused on adaptive immunotherapy, such as chimeric antigen receptor (CAR)-engineered T cells or NK cells, which have been showing remarkable promise for treating cancer. Creative Biolabs, as a leading technology provider, offers a variety of CARs targeting GCT-specific antigens.
With a great team of excellent scientists, we can provide customers with the highest quality bespoke CAR construction service according to your special needs.
Products ordering information
Please note: Besides the CARs targeting GCT-specific antigens listed below, we also provide highly customized service tailored to your research, diagnostic and therapeutic application purposes. We look forward to hearing from you.
|Associated malignancy||Target antigen||Receptor type||Product|
|Alpha(v) beta(6) integrin (αvβ6)||Bpep-CD4TM-CD3ζ||CAR-MZ229|
|NKG2D ligands||NKG2D receptor-CD28-CD3ζ||CAR-MZ233|
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE